Since SOCS2 changes the role of immune microenvironment in the development of NAFLD/NASH to HCC, it is very promising to use it as a target to prevent the malignant transformation of NAFLD/NASH in the future, so as to achieve the effect of primary prevention. Here, SOCS2 is linked to metabolic dysfunction-associated steatotic liver disease.